The efficacy and safety of Alglucosidase Alfa, a recombinant enzyme used in treating Pompe disease, are significantly affected by genetic variations in the GAA gene. These genetic differences influence both how patients process the drug and their therapeutic response, emphasizing the importance of GAA genotyping to tailor treatment plans and improve outcomes according to individual genetic profiles.